Clinical Trial

Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-22; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2026-07-15
Trial Details
NCT Number NCT06796803
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Conditions Potentially Resectable Hepatocellular Carcinoma
Enrollment 398 participants
Start Date 2025-02-20
Primary Completion 2028-02-20 (estimated)
Study Completion 2030-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-17